Cellular Peptide
Bremelanotide
Vyleesi
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
A 7-amino acid cyclic peptide analog of alpha-MSH that activates melanocortin receptors MC3R and MC4R, FDA-approved for hypoactive sexual desire disorder and studied for sexual function in clinical research. Premium Research Peptide.
Third Party Tested by Freedom Diagnostics
Technical specifications
Cyclic heptapeptide analog of alpha-MSH, active metabolite of Melanotan II
Cyclic Peptide
FDA Approved
Handle with care to maintain potency
Light sensitive
Refrigerate
Lyophilized (powder)
2-8°C • protect from light
Reconstituted
2-8°C • use within 30 days
Auto-injector (Vyleesi)
Room temperature
Developed by Palatin Technologies, approved by FDA
Peer-reviewed research
Obstetrics & Gynecology
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
2019 • DOI: 10.1097/AOG.
PMID: 31599840
Kingsberg SA, Clayton AH, Portman D,...
International Journal of Impotence Research
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
2004 • PMID: 12851303
Diamond LE, Earle DC, Rosen RC, et al.
Journal of Sexual Medicine
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by...
2006 • DOI: 10.1111/j.1743-6...
PMID: 16839319
Diamond LE, Earle DC, Heiman JR, et al.
Journal of Women's Health
Safety Profile of Bremelanotide Across the Clinical Development Program
2022
FDA
Vyleesi (bremelanotide) Prescribing Information
2019
Medicina (Kaunas)
Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder
2022 • PMID: 35056399
PubChem Database
Bremelanotide - Compound Summary (CID 9941379)
